First human test of BIIB144 begins: safety first
NCT ID NCT07662148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is the first time the experimental drug BIIB144 is given to humans. Researchers want to see if a single dose is safe and how the body handles it. About 48 healthy adults will receive either BIIB144 or a placebo by IV. The results will help decide if and how to test the drug in people with certain diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BIIB144
What this could lead to
If safe, this could pave the way for future studies of BIIB144 in people with specific diseases.
What could go wrong
This is a very early, first-in-human trial with only 48 healthy volunteers. The drug may cause side effects or not work as hoped in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••